RBOT vs. MLSS, LFWD, CLGN, NTRB, COCH, INGN, CALC, NEUE, HSAQ, and BLRX
Should you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Milestone Scientific (MLSS), ReWalk Robotics (LFWD), CollPlant Biotechnologies (CLGN), Nutriband (NTRB), Envoy Medical (COCH), Inogen (INGN), CalciMedica (CALC), NeueHealth (NEUE), Health Sciences Acquisitions Co. 2 (HSAQ), and BioLineRx (BLRX). These companies are all part of the "medical" sector.
Vicarious Surgical (NYSE:RBOT) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.
Vicarious Surgical has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Milestone Scientific has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
Vicarious Surgical has a net margin of 0.00% compared to Milestone Scientific's net margin of -70.50%. Vicarious Surgical's return on equity of -82.61% beat Milestone Scientific's return on equity.
Milestone Scientific has higher revenue and earnings than Vicarious Surgical. Milestone Scientific is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vicarious Surgical had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for Milestone Scientific. Vicarious Surgical's average media sentiment score of 0.20 beat Milestone Scientific's score of 0.00 indicating that Vicarious Surgical is being referred to more favorably in the media.
Vicarious Surgical received 8 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 38.10% of users gave Vicarious Surgical an outperform vote while only 0.00% of users gave Milestone Scientific an outperform vote.
Vicarious Surgical presently has a consensus target price of $0.67, suggesting a potential upside of 135.32%. Given Vicarious Surgical's higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Milestone Scientific.
47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are owned by institutional investors. 14.7% of Vicarious Surgical shares are owned by insiders. Comparatively, 25.2% of Milestone Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Vicarious Surgical beats Milestone Scientific on 10 of the 15 factors compared between the two stocks.
Get Vicarious Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vicarious Surgical Competitors List
Related Companies and Tools
